Videos

Here are the top 5 biosimilar articles for the week of April 1, 2024.

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Drs Lio, Botsoglou, and Alexrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Here are the top 5 biosimilar articles for the week of March 25, 2024.

Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering biosimilar access remains uncertain.

Here are the top 5 biosimilar articles for the week of March 18, 2024.

Here are the top 5 biosimilar articles for the week of March 11, 2024.

Intellectual property attorney, Ha Kung Wong, JD, discusses concerns about "bad patents" hindering biosimilar access, but assures that the FDA and United States Patent and Trademark Office are working to improve the system.

Here are the top 5 biosimilar articles for the week of March 4, 2024.

Here are the top 5 articles for the week of February 26, 2024.

Ha Kung Wong, JD, examines proposed patent law changes that could significantly impact the biosimilars sector, including limitations on asserted patents, elimination of interchangeability requirements, and heightened oversight of pharmacy benefit managers.

Here are the top 5 biosimilar articles for the week of February 19, 2024.

Here are the top 5 biosimilar articles for the week of February 12, 2024.

In an interview with Ha Kung Wong, JD, he addresses the patent legal system biosimilars are required to undergo and how this helps resolve patent disputes early in the development process.

Here are the top 5 biosimilar articles for the week of February 5, 2024.

Here are the top 5 biosimilar articles for the week of January 29, 2024.

Here are the top 5 biosimilar articles for the week of January 22, 2024.

Here are the top 5 biosimilar articles for the week of January 15, 2024.

Here are the top 5 biosimilar articles for the week of January 8, 2024.

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

Here are the top 5 biosimilar articles for the week of January 1, 2024.

Here are the top 5 biosimilar articles for 2023.

Brian Biehn and Corey Ford from Cencora suggest improvements to current regulatory frameworks to better promote biosimilars for US patients and ensure market sustainability.

Here are the top 5 biosimilar articles for the week of December 18th, 2023.

Here are the top 5 biosimilar articles for the week of December 11, 2023.

Brian Biehn, senior director of biosimilar commercialization at Cencora, makes predictions for how big regulatory approvals in 2023 will shape the biosimilar space going forward.

Here are the top 5 biosimilar articles for the week of December 4, 2023.

Here are the top 5 biosimilar articles for the week of November 27, 2023.

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, explains the purpose of dual-pricing strategies for adalimumab biosimilars and predicts whether these strategies will occur in other treatment spaces.

Here are the top 5 biosimilar articles for the week of November 20, 2023.